Global chronic pain won’t wait, and neither will we.

Ankerias enables personalized chronic pain treatment

and patient selection to renew global pain care.

Ankerias helps clinicians and healthcare working with chronic and neuropathic pain better diagnose pain mechanisms, identify suitable candidates for spinal cord stimulation (SCS), and optimize treatment outcomes.

Built on real-world health data and AI-assisted insights, our solution supports more precise decision-making from diagnosis to treatment optimization.

Read on ›
Ankerias_Tuote_SQR
Ankerias_Tuote_SQR

Ankerias helps clinicians and healthcare working with chronic and neuropathic pain better diagnose pain mechanisms, identify suitable candidates for spinal cord stimulation (SCS), and optimize treatment outcomes.

Built on real-world health data and AI-assisted insights, our solution supports more precise decision-making from diagnosis to treatment optimization.

Read on ›

Enabling more timely and personalized spinal cord stimulation (SCS) therapy for patients with chronic pain

Enabling more timely and personalized spinal cord stimulation (SCS) therapy for patient with chronic pain

Global chronic pain

Everyone deserves to live a healthy and pain-free life. Around 1.5 billion individuals globally suffer from chronic pain, with neuropathic pain affecting 7–10% of these cases. Too many are left in pain without adequate care, leading to ongoing suffering as pain mechanisms are often difficult to identify.

Spinal cord stimulation

Spinal cord stimulation (SCS) provides pain relief when other treatments don’t. SCS reduces pain in 40–80% of treated cases. Stimulation also reduces and stabilizes drug use. Moreover, it has been shown to significantly reduce healthcare costs.

However, less than 5% of eligible patients receive this treatment. Underutilization of effective care entails significant additional costs for societies and prolonged suffering for patients.

Ankerias’s solution

Ankerias provides healthcare professionals with a digital platform that enhances the treatment of chronic and neuropathic pain patients. Using pain diaries, data analysis, AI/ML and physiological modeling, we support assessment and clinical decision-making to personalize and target SCS pain therapy better.

Read testimonials ›

Spinal cord stimulation is a highly effective treatment for selected patients with chronic pain. However, identifying the right patients at the right time remains a challenge.

Many patients do not receive this therapy early enough to achieve optimal benefit. There is a clear need for a faster, smarter tool to support patient selection and therapy optimization.

— Dr. Mette Nissen, Consultant in Neurosurgery, Kuopio University Hospital

Spinal cord stimulation is a highly effective treatment for selected patients with chronic pain. However, identifying the right patients at the right time remains a challenge.

Many patients do not receive this therapy early enough to achieve optimal benefit. There is a clear need for a faster, smarter tool to support patient selection and therapy optimization.

— Dr. Mette Nissen, Consultant in Neurosurgery, Kuopio University Hospital

After years of trying treatments that didn’t work, I was finally offered spinal cord stimulation and it changed everything. I just wish it had come earlier.

— Spinal cord stimulation patient, Oulu, Finland

Our mission is to make effective pain treatment accessible sooner for chronic pain patients. By combining AI with clinical insight, we empower healthcare professionals to make more timely and targeted decisions.

— Hanna Viisanen-Kuopila, CEO & Co-Founder, Ankerias

Meet Ankerias ›
Patient-and-Clinician-Ankerias-White
Patient-and-Clinician-Ankerias-White

Spinal cord stimulation is a highly effective treatment for selected patients with chronic pain. However, identifying the right patients at the right time remains a challenge.

Many patients do not receive this therapy early enough to achieve optimal benefit. There is a clear need for a faster, smarter tool to support patient selection and therapy optimization.

— Dr. Mette Nissen, Consultant in Neurosurgery, Kuopio University Hospital

Spinal cord stimulation is a highly effective treatment for selected patients with chronic pain. However, identifying the right patients at the right time remains a challenge.

Many patients do not receive this therapy early enough to achieve optimal benefit. There is a clear need for a faster, smarter tool to support patient selection and therapy optimization.

— Dr. Mette Nissen, Consultant in Neurosurgery, Kuopio University Hospital

After years of trying treatments that didn’t work, I was finally offered spinal cord stimulation and it changed everything. I just wish it had come earlier.

— Spinal cord stimulation patient, Oulu, Finland

Our mission is to make effective pain treatment accessible sooner for chronic pain patients. By combining AI with clinical insight, we empower healthcare professionals to make more timely and targeted decisions.

— Hanna Viisanen-Kuopila, CEO & Co-Founder, Ankerias

Meet Ankerias ›

Meet Team Ankerias

Meet Team Ankerias

We have a very strong background in neuroscience, pain research, data analysis, and AI/ML applications.

Hanna Viisanen-Kuopila

Founder, CEO
PhD, Adj. Prof. in Physiology

Mette Nissen

Medical advisor

MD PhD, Consultant in Neurosurgery,
Kuopio University Hospital

Riku Tikkanen

Co-founder, CTO
MSc in Computer Science

Nitin Williams

Principal AI scientist
PhD, Adj. Prof. in Neuroinformatics University of Helsinki, Visiting researcher Aalto University

Let’s talk ›

Mikko Pitkänen

CFO
Master in Social Sciences

Tapio Jakobsson

Regulatory affairs and quality advisor

MSc in Technology

Pekka Männistö

Health economics advisor

MSc

Alexander Helmut Jung

AI/ML advisor

Associate Professor for ML,
Aalto University

Collaborators

Collaborators

Ankerias News

Follow Ankerias and track the progress of our project.

In 2025, we strengthened our clinical validation work through surveys and early-stage piloting. We also advanced our clinical AI software platform for complex neuropathic pain and SCS therapy and strengthened our research and development work.

In 2026, our focus is to move into the next validation phases, expand pilots, and continue developing the platform toward clinical adoption. We are also working toward first commercial deployments in the second half of the year.

Our pre-seed round is progressing, and we are open to connecting with additional investors.

Drop us a message and let’s talk. We are happy to share more about Ankerias and our solution!

Send us a message ›

Preparing for the next phase in 2026!

30.12.2025

2025 was a year of meaningful progress for Ankerias. We moved from concept to real-world validation and built the first MVP modules of our clinical software platform to support monitoring and clinical decision support in complex neuropathic pain care.

In 2025, we successfully completed a Business Finland Tempo project, strengthening our validation roadmap and sharpening our go-to-market direction. Alongside this, we built and tested the first MVP modules of our clinical software platform to support monitoring and clinical decision support in complex neuropathic pain and SCS therapy.

As part of our clinical development work, we conducted multiple surveys and early-stage pilots during the year. The most significant of these was carried out in collaboration with OuluHealth Labs and provided key insights to support product development and further validation. We also strengthened our research and development collaboration with the University of Oulu and expanded our network.

In 2025, the Ankerias core team strengthened and our expert network expanded. Product development and validation have been advanced through close collaboration across the team, advisors, and clinical and research partners.

In the second half of the year, we advanced our pre-seed round significantly and secured strong investor commitments. We expect to finalize the round in early 2027, and there is still room for additional investors to join.

In 2026, our focus is to expand pilots in Europe, strengthen clinical adoption, and continue developing the platform step by step. We are also working toward first sales in the second half of the year.

More information:
Hanna Viisanen-Kuopila, Founder, CEO hanna@ankerias.com

 

Ankerias founder and CEO selected for the Tech Nordic Advocates mentoring program

7.11.2025

Hanna Viisanen-Kuopila, founder and CEO of Ankerias, has been selected for the Tech Nordic Advocates (TNA) mentoring program. The program brings together talent across the Nordic tech ecosystem and provides mentoring and peer support for building and scaling growth companies.

The TNA mentoring program supports Ankerias’ mission to develop a clinical software platform for monitoring and clinical decision support in complex neuropathic pain care. The program provides valuable perspectives on international growth, partnerships, and scaling.

We thank Tech Nordic Advocates for the opportunity and look forward to learning and collaborating within the network.

Ankerias advances clinical validation with OuluHealth Labs

1.9.2025

Ankerias strengthened its clinical validation work in collaboration with OuluHealth Labs by conducting a survey among healthcare professionals. The insights have already informed our product development and validation planning.

The purpose of the survey was to deepen our understanding of real-world chronic pain care workflows and to identify what information and decision support clinicians need in complex neuropathic pain care.

The results were used to guide the development of Ankerias’ clinical software platform, combining care monitoring and decision support for complex neuropathic pain and SCS therapy.

The feedback has helped ensure that our solution fits real clinical workflows and meets healthcare professionals’ needs. It has also supported planning for future validation and adoption phases.

This survey was part of a broader collaboration with OuluHealth Labs, where we explored perspectives from both healthcare professionals and patients related to complex neuropathic pain care and conducted early-stage piloting activities. The collaboration has provided valuable input for product development and the planning of further validation.

We would like to thank OuluHealth Labs and all participating healthcare professionals for their valuable input.

More information:
Hanna Viisanen-Kuopila, CEO
hanna@ankerias.com

 

 

 

Representing Finnish Healthtech & AI at TechBBQ 2025

20.8.2025

We’re excited to share that Ankerias has been selected to join the Business Helsinki AiStart incubator and Health Incubator Helsinki delegation to TechBBQ 2025 Copenhagen Denmark, one of the leading startup and tech events Europe.

This delegation brings together Finnish deep tech and healthtech startups with international investors, partners, and ecosystem players.

Participation in the delegation supports our goal to expand Ankerias internationally, build connections within the global healthtech ecosystem, and meet potential collaborators and investors working at the intersection of AI and healthcare.

Read more about the TechBBQ 2025 event >. 

More about the Finnish AI & Health delegation (AiStart LinkedIn post >).

 

 

Ankerias accepted into Google for Startups Cloud program

19.8.2025

We’re excited to announce that Ankerias has been selected to join the Google for Startups Cloud program.

This opportunity gives us access to Google’s world-class cloud infrastructure, enabling faster and more secure development of our AI-powered platform for chronic pain care — with a focus on spinal cord stimulation (SCS).

At Ankerias, we’re building tools to help clinicians identify the right patients for neuromodulation treatments and monitor treatment outcomes using real-world data. With Google Cloud, we can now process complex clinical datasets at scale, supporting our mission to deliver trustworthy AI in healthcare.

 

 

Collaboration with the University of Oulu Strengthens AI Development Team

1.7.2025

We’re happy to announce that Ankerias has begun a new collaboration with the University of Oulu, Faculty of Information Technology and Electrical Engineering.

As part of this initiative, a new expert has joined Ankerias to support the development of our AI platform for chronic pain care — strengthening our technical capabilities and bringing fresh insight into digital health.

This collaboration reflects our commitment to working closely with academic institutions and future talent, ensuring a strong connection between research, emerging technologies, and real-world clinical applications.

It also deepens our ties to Finland’s vibrant healthtech ecosystem, and supports our long-term mission of delivering trusted, data-driven solutions in chronic pain care.

 

Ankerias successfully completes first patient testing phase in Oulu

12.2.2025

We have reached a significant milestone in our mission to revolutionize chronic pain treatment – the first testing phase of our solution is now successfully completed! This is an important step forward in developing a more innovative and personalized approach to pain management.

The testing was carried out in collaboration with the OuluHealth ecosystem, Pohjois-Pohjanmaan hyvinvointialue (Pohde), and OYS TestLab. Their cutting-edge infrastructure and expertise provided an excellent environment to validate our technology and further refine our approach.

The insights gained during this phase will help us further develop and refine our solution.

Ankerias secures Business Finland's Tempo Funding to revolutionize chronic pain treatment

17.10.2024

We are excited to announce that Ankerias Oy has been granted Business Finland's Tempo funding. This support will help us accelerate our mission to revolutionize the treatment of chronic pain.

 

 

 

 

Ankerias has moved to Terkko Health Hub in Meilahti, Helsinki!

1.10.2024

Great news — again! Ankerias has moved to Terkko Health Hub in Meilahti, Helsinki. Meilahti is the home to the leading Finnish hospital Helsinki University Central Hospital, the Medical faculty of University of Helsinki, and many innovative healthtech companies.

Our new location and Terkko Health Hub offer us a better access to key healthcare professionals, a vibrant start-up ecosystem and exciting networking opportunities.

We look forward to seeing what this change will bring to our growth and innovation together with Health Incubator Helsinki!

Our journey with the Health Incubator Helsinki Program!

10.9.2024

We’re thrilled to announce that our journey in the Health Incubator Helsinki Program is now underway.

The Health Incubator Helsinki recently published a news article about our story and what lies ahead. You can read it here >.

Our mission is to create a future where chronic pain patients can live satisfying and pain-free lives, thanks to cutting-edge technology.

The program’s mentorship, networking opportunities, and infrastructure are helping us accelerate our growth and development.

Great news! Ankerias has been selected for
the Health Incubator Helsinki program!

28.5.2024

We have great news! Ankerias Oy has been selected for the Health Incubator Helsinki program together with 9 other teams.

This collaboration is significant for us and is a big step forward in our commitment to integrate health, software technology and artificial intelligence to transform healthcare and chronic pain treatments.

Read more about the program here ›

Thanks to all our team members, partners, and advisors. Special thanks to our advisors Pekka Männistö, Mette Nissen and Alexander Jung. We are eager to start the next phase of our journey!

Let’s treat chronic pain together!

Empowering Chronic Pain Management:
Our Journey with the Nexus Program

29.2.2024

At Ankerias, we are committed to revolutionizing healthcare solutions for chronic pain. Our dedication to this mission led us to participate in the Nexus program, an incubator and accelerator initiative designed to support startups in the field of AI, Deep Tech, and sustainability.

The Nexus program provided us with a unique opportunity to collaborate with mentors, experts, and fellow entrepreneurs who share our passion for innovation in healthcare. From the kick-off event to the final Demo Day, every moment spent in the program was filled with learning, growth, and inspiration.

One of the most significant benefits of the Nexus program was the mentorship and guidance we received from experienced professionals. Through workshops, one-on-one sessions, and networking events, we gained valuable insights into various aspects of entrepreneurship, including pitching, business model development, corporate innovation, and team building. These insights have helped us shape our startup journey and refining our approach to addressing the complex challenges of chronic pain management.

Moreover, the Nexus program provided us with access to a supportive network of like-minded individuals. We had the opportunity to connect with investors, corporates, and industry experts who provided feedback, guidance, and potential partnerships. This network has been invaluable in accelerating our growth and expanding our reach within the healthcare industry.

We look forward to applying the lessons learned and continuing to innovate and collaborate as we strive to revolutionize healthcare solutions for those in need!

Our journey began in HealthX and Nexus incubator programs in 2023.

19.1.2024

Ankerias’s journey began with participation in the HealthX pre-incubator program. Our team had a vision and a common goal of improving the wellbeing of chronic pain patients. The team wanted to combine their expertise to create game-changing solutions for the healthcare sector. The HealthX program was instrumental in leveraging our shared skills and knowledge, leading to the development of our initial concept and participation in the next phase — the Nexus incubator program. This is where Ankerias turned from an idea into a reality, culminating in the founding of our company in late 2023.

The programs have been a significant step in our journey as a startup company. These programs have helped us develop our business model, network with industry experts, and helped us access important resources. In addition, we have networked with other innovators and are now in a better position to bring our solutions to market.

We are grateful for our journey in the programs. Stay tuned for more updates on our progress in pain management.

Check out Nexus incubator program website ›

Ankerias News

Follow Ankerias and track the progress of our project.

In 2025, we strengthened our clinical validation work through surveys and early-stage piloting. We also advanced our clinical AI software platform for complex neuropathic pain and SCS therapy and strengthened our research and development work.

In 2026, our focus is to move into the next validation phases, expand pilots, and continue developing the platform toward clinical adoption. We are also working toward first commercial deployments in the second half of the year.

Our pre-seed round is progressing, and we are open to connecting with additional investors.

Drop us a message and let’s talk. We are happy to share more about Ankerias and our solution!

Send us a message ›

Preparing for the next phase in 2026

30.12.2025

2025 was a year of meaningful progress for Ankerias. We moved from concept to real-world validation and built the first MVP modules of our clinical software platform to support monitoring and clinical decision support in complex neuropathic pain care.

In 2025, we successfully completed a Business Finland Tempo project, strengthening our validation roadmap and sharpening our go-to-market direction. Alongside this, we built and tested the first MVP modules of our clinical software platform to support monitoring and clinical decision support in complex neuropathic pain and SCS therapy.

As part of our clinical development work, we conducted multiple surveys and early-stage pilots during the year. The most significant of these was carried out in collaboration with OuluHealth Labs and provided key insights to support product development and further validation. We also strengthened our research and development collaboration with the University of Oulu and expanded our network.

In 2025, the Ankerias core team strengthened and our expert network expanded. Product development and validation have been advanced through close collaboration across the team, advisors, and clinical and research partners.

In the second half of the year, we advanced our pre-seed round significantly and secured strong investor commitments. We expect to finalize the round in early 2027, and there is still room for additional investors to join.

In 2026, our focus is to expand pilots in Europe, strengthen clinical adoption, and continue developing the platform step by step. We are also working toward first sales in the second half of the year.

More information:
Hanna Viisanen-Kuopila, Founder, CEO hanna@ankerias.com

Ankerias founder and CEO selected for the Tech Nordic Advocates mentoring program

7.11.2025

Hanna Viisanen-Kuopila, founder and CEO of Ankerias, has been selected for the Tech Nordic Advocates (TNA) mentoring program. The program brings together talent across the Nordic tech ecosystem and provides mentoring and peer support for building and scaling growth companies.

The TNA mentoring program supports Ankerias’ mission to develop a clinical software platform for monitoring and clinical decision support in complex neuropathic pain care. The program provides valuable perspectives on international growth, partnerships, and scaling.

We thank Tech Nordic Advocates for the opportunity and look forward to learning and collaborating within the network.

Ankerias advances clinical validation with OuluHealth Labs

1.9.2025

Ankerias strengthened its clinical validation work in collaboration with OuluHealth Labs by conducting a survey among healthcare professionals. The insights have already informed our product development and validation planning.

The purpose of the survey was to deepen our understanding of real-world chronic pain care workflows and to identify what information and decision support clinicians need in complex neuropathic pain care.

The results were used to guide the development of Ankerias’ clinical software platform, combining care monitoring and decision support for complex neuropathic pain and SCS therapy.

The feedback has helped ensure that our solution fits real clinical workflows and meets healthcare professionals’ needs. It has also supported planning for future validation and adoption phases.

This survey was part of a broader collaboration with OuluHealth Labs, where we explored perspectives from both healthcare professionals and patients related to complex neuropathic pain care and conducted early-stage piloting activities. The collaboration has provided valuable input for product development and the planning of further validation.

We would like to thank OuluHealth Labs and all participating healthcare professionals for their valuable input.

More information:
Hanna Viisanen-Kuopila, CEO
hanna@ankerias.com

 

Representing Finnish Healthtech & AI at TechBBQ 2025

20.8.2025

We’re excited to share that Ankerias has been selected to join the Business Helsinki AiStart incubator and Health Incubator Helsinki delegation to TechBBQ 2025 Copenhagen Denmark, one of the leading startup and tech events Europe.

This delegation brings together Finnish deep tech and healthtech startups with international investors, partners, and ecosystem players.

Participation in the delegation supports our goal to expand Ankerias internationally, build connections within the global healthtech ecosystem, and meet potential collaborators and investors working at the intersection of AI and healthcare.

Read more about the TechBBQ 2025 event >. 

More about the Finnish AI & Health delegation (AiStart LinkedIn post >).

Ankerias accepted into Google for Startups Cloud program

19.8.2025

We’re excited to announce that Ankerias has been selected to join the Google for Startups Cloud program.

This opportunity gives us access to Google’s world-class cloud infrastructure, enabling faster and more secure development of our AI-powered platform for chronic pain care — with a focus on spinal cord stimulation (SCS).

At Ankerias, we’re building tools to help clinicians identify the right patients for neuromodulation treatments and monitor treatment outcomes using real-world data. With Google Cloud, we can now process complex clinical datasets at scale, supporting our mission to deliver trustworthy AI in healthcare.

Collaboration with the University of Oulu strengthens AI development team

1.7.2025

We’re happy to announce that Ankerias has begun a new collaboration with the University of Oulu, Faculty of Information Technology and Electrical Engineering.

As part of this initiative, a new expert has joined Ankerias to support the development of our AI platform for chronic pain care — strengthening our technical capabilities and bringing fresh insight into digital health.

This collaboration reflects our commitment to working closely with academic institutions and future talent, ensuring a strong connection between research, emerging technologies, and real-world clinical applications.

It also deepens our ties to Finland’s vibrant healthtech ecosystem, and supports our long-term mission of delivering trusted, data-driven solutions in chronic pain care.

Ankerias successfully completes first patient testing phase in Oulu

12.2.2025

We have reached a significant milestone in our mission to revolutionize chronic pain treatment – the first testing phase of our solution is now successfully completed! This is an important step forward in developing a more innovative and personalized approach to pain management.

The testing was carried out in collaboration with the OuluHealth ecosystem, Pohjois-Pohjanmaan hyvinvointialue (Pohde), and OYS TestLab. Their cutting-edge infrastructure and expertise provided an excellent environment to validate our technology and further refine our approach.

The insights gained during this phase will help us further develop and refine our solution.

Ankerias secures Business Finland's Tempo Funding to revolutionize chronic pain treatment

17.10.2024

We are excited to announce that Ankerias Oy has been granted Business Finland's Tempo funding. This support will help us accelerate our mission to revolutionize the treatment of chronic pain.

Ankerias has moved to Terkko Health Hub in Meilahti, Helsinki!

1.10.2024

Great news — again! Ankerias has moved to Terkko Health Hub in Meilahti, Helsinki. Meilahti is the home to the leading Finnish hospital Helsinki University Central Hospital, the Medical faculty of University of Helsinki, and many innovative healthtech companies.

Our new location and Terkko Health Hub offer us a better access to key healthcare professionals, a vibrant start-up ecosystem and exciting networking opportunities.

We look forward to seeing what this change will bring to our growth and innovation together with Health Incubator Helsinki!

Great news! Ankerias has been selected for
the Health Incubator Helsinki program!

28.5.2024

We have great news! Ankerias Oy has been selected for the Health Incubator Helsinki program together with 9 other teams.

This collaboration is significant for us and is a big step forward in our commitment to integrate health, software technology and artificial intelligence to transform healthcare and chronic pain treatments.

Read more about the program here ›

Thanks to all our team members, partners, and advisors. Special thanks to our advisors Pekka Männistö, Mette Nissen and Alexander Jung. We are eager to start the next phase of our journey!

Let’s treat chronic pain together!

Our journey began in HealthX and Nexus incubator programs in 2023.

29.2.2024

At Ankerias, we are committed to revolutionizing healthcare solutions for chronic pain. Our dedication to this mission led us to participate in the Nexus program, an incubator and accelerator initiative designed to support startups in the field of AI, Deep Tech, and sustainability.

The Nexus program provided us with a unique opportunity to collaborate with mentors, experts, and fellow entrepreneurs who share our passion for innovation in healthcare. From the kick-off event to the final Demo Day, every moment spent in the program was filled with learning, growth, and inspiration.

One of the most significant benefits of the Nexus program was the mentorship and guidance we received from experienced professionals. Through workshops, one-on-one sessions, and networking events, we gained valuable insights into various aspects of entrepreneurship, including pitching, business model development, corporate innovation, and team building. These insights have helped us shape our startup journey and refining our approach to addressing the complex challenges of chronic pain management.

Moreover, the Nexus program provided us with access to a supportive network of like-minded individuals. We had the opportunity to connect with investors, corporates, and industry experts who provided feedback, guidance, and potential partnerships. This network has been invaluable in accelerating our growth and expanding our reach within the healthcare industry.

We look forward to applying the lessons learned and continuing to innovate and collaborate as we strive to revolutionize healthcare solutions for those in need!

Our journey began in HealthX and Nexus incubator programs in 2023.

19.1.2024

Ankerias’s journey began with participation in the HealthX pre-incubator program. Our team had a vision and a common goal of improving the wellbeing of chronic pain patients. The team wanted to combine their expertise to create game-changing solutions for the healthcare sector. The HealthX program was instrumental in leveraging our shared skills and knowledge, leading to the development of our initial concept and participation in the next phase — the Nexus incubator program. This is where Ankerias turned from an idea into a reality, culminating in the founding of our company in late 2023.

The programs have been a significant step in our journey as a startup company. These programs have helped us develop our business model, network with industry experts, and helped us access important resources. In addition, we have networked with other innovators and are now in a better position to bring our solutions to market.

We are grateful for our journey in the programs. Stay tuned for more updates on our progress in pain management.

Check out Nexus incubator program website ›

We are looking for investors and partners!

Interested to hear more? Contact us.

Ankerias is based in Espoo and Helsinki, Finland.

Let’s organize a meeting so we can look at Ankerias’s solution in detail, face to face or online.

We should discuss how we could collaborate with you and your organization!

Interested to hear more? Contact us.

Ankerias is based in Espoo and Helsinki, Finland.

Let’s organize a meeting so we can look at Ankerias’s solution in detail, face to face or online.

We should discuss how we could collaborate with you and your organization!

Drop us a message!

Drop us a message!

Name